PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with multiple sclerosis (MS) are at higher risk of having infections due to receiving disease modifying therapies. The current study was conducted among Iranian MS patients who had experienced at least one episode of COVID-19 infection in order to evaluate the effects of COVID-19 vaccination on symptoms of their infection. Data on demographic information, MS characteristics, COVID-19 infection details, and vaccination status were collected. Statistical analyses, were performed to evaluate the association between vaccination and symptoms of COVID-19 infection.
UNASSIGNED: This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients\' who declared to be vaccinated was checked by their COVID-19 vaccination card.
UNASSIGNED: A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (P-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, P-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, P-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39).
UNASSIGNED: COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination.
UNASSIGNED: This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients\' who declared to be vaccinated was checked by their COVID-19 vaccination card.
UNASSIGNED: A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (P-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, P-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, P-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39).
UNASSIGNED: COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination.
摘要：
患有多发性硬化症(MS)的患者由于接受疾病改善疗法而具有较高的感染风险。本研究是在至少经历过一次COVID-19感染的伊朗MS患者中进行的，目的是评估COVID-19疫苗接种对其感染症状的影响。人口统计信息数据，MS特性，COVID-19感染细节，并收集疫苗接种情况。统计分析，进行评估疫苗接种与COVID-19感染症状之间的关系。
■这项横断面研究是对确诊的MS患者进行的。通过在线问卷收集了人口统计学数据和COVID-19相关症状。通过他们的COVID-19疫苗接种卡检查宣布接种疫苗的患者的确认情况。
■共有236名MS患者参与了这项研究。大多数是女性(79.7%)，平均年龄36.1±7.9岁。在参与者中，72.5%的人在首次感染COVID-19之前已经接种了COVID-19疫苗。分析显示，接种疫苗和未接种疫苗的个体之间呼吸道症状（P值：0.01）和头痛（P值：0.04）的发生率存在显着差异。Logistic回归分析显示，在下一次COVID-19感染发作期间，接种疫苗的MS患者出现呼吸道症状（OR：0.29，95%CI：0.16至0.53，P值<0.001）或头痛（OR：0.50，95%CI：0.25至0.98，P值：0.04）的几率较低。此外，接受免疫抑制药物的MS患者不太可能出现呼吸道症状（OR：0.35，95％CI：0.16至0.77，P值：0.009），但没有头痛（OR：0.69，95％CI：0.30至1.60，P值：0.39）。
■COVID-19疫苗接种可以减少MS患者在COVID-19感染发作期间呼吸道症状和头痛的发生率。此外,正在接受免疫抑制药物治疗的患者可从COVID-19疫苗接种中获益.
■这项横断面研究是对确诊的MS患者进行的。通过在线问卷收集了人口统计学数据和COVID-19相关症状。通过他们的COVID-19疫苗接种卡检查宣布接种疫苗的患者的确认情况。
■共有236名MS患者参与了这项研究。大多数是女性(79.7%)，平均年龄36.1±7.9岁。在参与者中，72.5%的人在首次感染COVID-19之前已经接种了COVID-19疫苗。分析显示，接种疫苗和未接种疫苗的个体之间呼吸道症状（P值：0.01）和头痛（P值：0.04）的发生率存在显着差异。Logistic回归分析显示，在下一次COVID-19感染发作期间，接种疫苗的MS患者出现呼吸道症状（OR：0.29，95%CI：0.16至0.53，P值<0.001）或头痛（OR：0.50，95%CI：0.25至0.98，P值：0.04）的几率较低。此外，接受免疫抑制药物的MS患者不太可能出现呼吸道症状（OR：0.35，95％CI：0.16至0.77，P值：0.009），但没有头痛（OR：0.69，95％CI：0.30至1.60，P值：0.39）。
■COVID-19疫苗接种可以减少MS患者在COVID-19感染发作期间呼吸道症状和头痛的发生率。此外,正在接受免疫抑制药物治疗的患者可从COVID-19疫苗接种中获益.
